Ziopharm Oncology Inc. (NASDAQ:ZIOP) shares fell 3% during trading on Thursday . The company traded as low as $4.92 and last traded at $4.92, with a volume of 964,637 shares. The stock had previously closed at $5.07.

A number of research firms have recently commented on ZIOP. Zacks Investment Research raised shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a report on Tuesday, August 16th. Griffin Securities reissued a “buy” rating and issued a $21.00 target price on shares of Ziopharm Oncology in a report on Monday, August 15th. Wells Fargo & Co. raised shares of Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Mizuho reissued a “neutral” rating and issued a $5.00 target price (down previously from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Finally, Raymond James Financial Inc. began coverage on shares of Ziopharm Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating for the company. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $9.75.

The stock’s 50-day moving average is $5.18 and its 200-day moving average is $6.75. The stock’s market capitalization is $651.18 million.

Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.90. The company earned $1.70 million during the quarter, compared to the consensus estimate of $1.52 million. During the same period in the prior year, the business posted ($0.11) earnings per share. The business’s revenue was up 525.0% compared to the same quarter last year. On average, analysts expect that Ziopharm Oncology Inc. will post ($1.15) EPS for the current fiscal year.

An institutional investor recently raised its position in Ziopharm Oncology stock. Morgan Stanley increased its position in shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,618,205 shares of the biotechnology company’s stock after buying an additional 78,583 shares during the period. Morgan Stanley owned about 1.25% of Ziopharm Oncology worth $13,447,000 at the end of the most recent quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.